跳至主要内容
临床试验/NL-OMON31209
NL-OMON31209尚未招募2 期

Safety and efficacy of hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients. Part B: Clinical Study Protocol SC13: Safety of a 5 mg dose of hLF1-11 given for 10 consecutive days to autologous haematopoietic stem cell transplant recipients - Safety of hLF1-11 in autologous HSCTrecipients

AM-Pharma0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • · has been admitted for an autologous HSCT after myeloablative therapy with
  • high-dose melphalan;
  • · is being managed with a 3 or 4-lumen central venous catheter;
  • · is at least 18 years old;
  • · has a BMI < 30 kg/M2;
  • · has no medical reason for not participating;
  • · has adequate renal function (creatinine < 1.5 x ULN) ;
  • · has adequate liver function (ASAT, ALAT < 2.5 x ULN, bilirubin < 1.5 x ULN);
  • · if a woman, is functionally post-menopausal;
  • · has not participated in a study of a new chemical molecular entity in the
  • previous 3 months;
  • · is able and willing to participate;
  • · has provided written informed consent.

排除标准

  • Not applicable

研究者

发起方
AM-Pharma

相似试验